Palliation of hepatic tumors

Surgical Oncology

Volumn 16, Issue 4, 2007, Pages 277-291

  Cunningham, Steven C ^a   Choti, Michael A ^b   Bellavance, Emily C ^a   Pawlik, Timothy M ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatic tumors; Interventions; Palliation; Symptom relief

Indexed keywords

BETA CATENIN; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; OCTREOTIDE; OXALIPLATIN; PANITUMUMAB; PROTEIN KINASE B; SORAFENIB; WNT PROTEIN;

ADRENAL METASTASIS; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHOLANGITIS; COLORECTAL CARCINOMA; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NEUROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; PERITONEUM METASTASIS; PRIORITY JOURNAL; REVIEW; SYMPTOM;

CARCINOMA, HEPATOCELLULAR; CARCINOMA, NEUROENDOCRINE; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; HUMANS; LIVER FAILURE; LIVER NEOPLASMS; PALLIATIVE CARE; PROGNOSIS;

EID: 36649008720     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2007.08.010     Document Type: Review

References (166)

1. Cousins J.W. In: Warvi W.N. (Ed). Primary tumors of the liver vol. 80 (1945) 643-650
2. McClusky III D.A., Skandalakis L.J., Colborn G.L., and Skandalakis J.E. Hepatic surgery and hepatic surgical anatomy: historical partners in progress. World Journal of Surgery 21 3 (1997) 330-342
3. Langenbuch D. Ein Fall von Resection eines linksseitigen Schnurlappend der Leber. Heilung Verl Klin Wochenschr 25 (1888) 37-38
4. Miner T.J. Palliative surgery for advanced cancer: lessons learned in patient selection and outcome assessment. American Journal of Clinical Oncology 28 4 (2005) 411-414
5. Miner T.J., Brennan M.F., and Jaques D.P. A prospective, symptom related, outcomes analysis of 1022 palliative procedures for advanced cancer. Annals of Surgery 240 4 (2004) 719-726 discussion 726-7
6. Miner T.J., Jaques D.P., Tavaf-Motamen H., and Shriver C.D. Decision making on surgical palliation based on patient outcome data. American Journal of Surgery 177 2 (1999) 150-154
7. Krouse R.S., Chu D.Z., Grant M., et al. Evaluation of quality of life (QOL) in pancreaticoduodenectomy survivors. Annals of Surgery 235 2 (2002) 310-311
8. Simpson J. In: Simpson J. (Ed). Oxford english dictionary. 3rd ed (2007), Oxford University Press, Oxford
9. McCahill L.E., Dunn G.P., Mosenthal A.C., et al. Palliation as a core surgical principle: part 2. Journal of the American College of Surgeons 199 2 (2004) 321-334
10. McCahill L.E., Dunn G.P., Mosenthal A.C., et al. Palliation as a core surgical principle: part 1. Journal of the American College of Surgeons 199 1 (2004) 149-160
11. DeOliveira M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of Surgery 245 5 (2007) 755-762
12. Forner A., Hessheimer A.J., Isabel Real M., and Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 60 2 (2006) 89-98
13. Bergsland E.K., and Venook A.P. Hepatocellular carcinoma. Current Opinion in Oncology 12 4 (2000) 357-361
14. Sanchez W., and Talwalkar J.A. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterology Clinics of North America 35 1 (2006) 201-219
15. Kulke M.H., and Mayer R.J. Carcinoid tumors. New England Journal of Medicine 340 11 (1999) 858-868
16. Petry J.J. Surgery and meaning. Surgery 127 4 (2000) 363-365
17. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 7 (2007) 2557-2576
18. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 5 Suppl. 1 (2004) S27-S34
19. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Annals of Internal Medicine 139 10 (2003) 817-823
20. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 4 (1985) 918-928
21. Yeung Y.P., Lo C.M., Liu C.L., et al. Natural history of untreated nonsurgical hepatocellular carcinoma. American Journal of Gastroenterology 100 9 (2005) 1995-2004
22. El-Serag H.B., Siegel A.B., Davila J.A., et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. Journal of Hepatology 44 1 (2006) 158-166
23. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Seminars in Liver Disease 24 2 (2004) 115-125
24. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 57 1 (2007) 43-66
25. Arnold R., Rinke A., Schmidt C., and Hofbauer L. Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Practice and Research in Clinical Gastroenterology 19 4 (2005) 649-656
26. Cunningham S.C., Suh H.S., Winter J.M., et al. Retroperitoneal paraganglioma: single-institution experience and review of the literature. Journal of Gastrointestinal Surgery 10 8 (2006) 1156-1163
27. Brenner B., Tang L.H., Klimstra D.S., and Kelsen D.P. Small-cell carcinomas of the gastrointestinal tract: a review. Journal of Clinical Oncology 22 13 (2004) 2730-2739
28. Modlin I.M., Kidd M., and Lye K.D. Biology and management of gastric carcinoid tumours: a review. European Journal of Surgery 168 12 (2002) 669-683
29. Kuvshinoff B., and Fong Y. Surgical therapy of liver metastases. Seminars in Oncology 34 3 (2007) 177-185
30. Jarnagin W.R., Gonen M., Fong Y., et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Annals of Surgery 236 4 (2002) 397-406 discussion 406-7
31. Lau W.Y., Leung T.W., Leung K.L., et al. Cytoreductive surgery for hepatocellular carcinoma. Surgical Oncology 3 3 (1994) 161-166
32. Nagashima J., Okuda K., Tanaka M., et al. Prognostic benefit in cytoreductive surgery for curatively unresectable hepatocellular carcinoma-comparison to transcatheter arterial chemoembolization. International Journal of Oncology 15 6 (1999) 1117-1123
33. Rerknimitr R., Kladcharoen N., Mahachai V., and Kullavanijaya P. Result of endoscopic biliary drainage in hilar cholangiocarcinoma. Journal of Clinical Gastroenterology 38 6 (2004) 518-523
34. House M.G., and Choti M.A. Palliative therapy for pancreatic/biliary cancer. Surgical Clinics of North America 85 2 (2005) 359-371
35. Singhal D., van Gulik T.M., and Gouma D.J. Palliative management of hilar cholangiocarcinoma. Surgical Oncology 14 2 (2005) 59-74
36. Traynor O., Castaing D., and Bismuth H. Left intrahepatic cholangio-enteric anastomosis (round ligament approach): an effective palliative treatment for hilar cancers. British Journal of Surgery 74 10 (1987) 952-954
37. Guthrie C.M., Banting S.W., Garden O.J., and Carter D.C. Segment III cholangiojejunostomy for palliation of malignant hilar obstruction. British Journal of Surgery 81 11 (1994) 1639-1641
38. Smith A.C., Dowsett J.F., Russell R.C., et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 344 8938 (1994) 1655-1660
39. Figueras J., Llado L., Valls C., et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transplantation 6 6 (2000) 786-794
40. Wei A.C., Greig P.D., Grant D., et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Annals of Surgical Oncology 13 5 (2006) 668-676
41. Pawlik T.M., Scoggins C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Annals of Surgery 241 5 (2005) 715-722 discussion 722-4
42. Fernandez F.G., Drebin J.A., Linehan D.C., et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of Surgery 240 3 (2004) 438-447 discussion 447-50
43. Oshowo A., Gillams A., Harrison E., et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. British Journal of Surgery 90 10 (2003) 1240-1243
44. Belli G., D'Agostino A., Ciciliano F., et al. Liver resection for hepatic metastases: 15 years of experience. Journal of Hepatobiliary and Pancreatic Surgery 9 5 (2002) 607-613
45. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Annals of Surgery 235 6 (2002) 759-766
46. Minagawa M., Makuuchi M., Torzilli G., et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Annals of Surgery 231 4 (2000) 487-499
47. Fong Y., Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of Surgery 230 3 (1999) 309-318 discussion 318-21
48. Pawlik T.M., and Choti M.A. Surgical therapy for colorectal metastases to the liver. Journal of Gastrointestinal Surgery 11 8 (2007) 1057-1077
49. Kokudo N., Imamura H., Sugawara Y., et al. Surgery for multiple hepatic colorectal metastases. Journal of Hepatobiliary and Pancreatic Surgery 11 2 (2004) 84-91
50. Altendorf-Hofmann A., and Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surgical Oncology Clinics of North America 12 1 (2003) 165-192 xi
51. Pawlik T.M., Abdalla E.K., Ellis L.M., et al. Debunking dogma: surgery for four or more colorectal liver metastases is justified. Journal of Gastrointestinal Surgery 10 2 (2006) 240-248
52. Weber S.M., Jarnagin W.R., DeMatteo R.P., et al. Survival after resection of multiple hepatic colorectal metastases. Annals of Surgical Oncology 7 9 (2000) 643-650
53. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. American Journal of Surgery 169 1 (1995) 36-42 discussion 42-3
54. Sarmiento J.M., Heywood G., Rubin J., et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 197 1 (2003) 29-37
55. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. Journal of the American College of Surgeons 190 4 (2000) 432-445
56. Chen H., Hardacre J.M., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. Journal of the American College of Surgeons 187 1 (1998) 88-92 discussion 92-3
57. Sarmiento J.M., and Que F.G. Hepatic surgery for metastases from neuroendocrine tumors. Surgical Oncology Clinics of North America 12 1 (2003) 231-242
58. Sarmiento J.M., Que F.G., and Nagorney D.M. Surgical outcomes of isolated caudate lobe resection: a single series of 19 patients. Surgery 132 4 (2002) 697-708 discussion 708-9
59. McEntee G.P., Nagorney D.M., Kvols L.K., et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108 6 (1990) 1091-1096
60. de Herder W.W., Krenning E.P., Van Eijck C.H., and Lamberts S.W. Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. Endocrine-Related Cancer 11 1 (2004) 19-34
61. Connolly H.M. Carcinoid heart disease: medical and surgical considerations. Cancer Control 8 5 (2001) 454-460
62. Le Treut Y.P., Delpero J.R., Dousset B., et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Annals of Surgery 225 4 (1997) 355-364
63. Coppa J., Pulvirenti A., Schiavo M., et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplantation Proceedings 33 1-2 (2001) 1537-1539
64. Routley D., Ramage J.K., McPeake J., et al. Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transplantation and Surgery 1 2 (1995) 118-121
65. Olausson M., Friman S., Cahlin C., et al. Indications and results of liver transplantation in patients with neuroendocrine tumors. World Journal of Surgery 26 8 (2002) 998-1004
66. Florman S., Toure B., Kim L., et al. Liver transplantation for neuroendocrine tumors. Journal of Gastrointestinal Surgery 8 2 (2004) 208-212
67. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. New England Journal of Medicine 352 5 (2005) 476-487
68. Roberts L.R., and Gores G.J. Emerging drugs for hepatocellular carcinoma. Expert Opinion on Emerging Drug 11 3 (2006) 469-487
69. Khan S.A., Thomas H.C., Davidson B.R., and Taylor-Robinson S.D. Cholangiocarcinoma. Lancet 366 9493 (2005) 1303-1314
70. Mayer R.J. Moving beyond fluorouracil for colorectal cancer. New England Journal of Medicine 343 13 (2000) 963-964
71. Project A.C.C.M.-A. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Journal of Clinical Oncology 10 6 (1992) 896-903
72. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 9209 (2000) 1041-1047
73. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine 343 13 (2000) 905-914
74. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 350 23 (2004) 2335-2342
75. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 22 2 (2004) 229-237
76. Kelly H., and Goldberg R.M. Systemic therapy for metastatic colorectal cancer: current options, current evidence. Journal of Clinical Oncology 23 20 (2005) 4553-4560
77. Pestalozzi B.C. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 344 4 (2001) 306 author reply 306-7
78. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology 25 13 (2007) 1670-1676
79. Leong W.L., and Pasieka J.L. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. Journal of Surgical Oncology 79 3 (2002) 180-187
80. Moertel C.G., Kvols L.K., O'Connell M.J., and Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 2 (1991) 227-232
81. Moertel C.G., Kvols L.K., and Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67 1 (1991) 33-36
82. Kaltsas G.A., Mukherjee J.J., Isidori A., et al. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clinical Endocrinology (Oxford) 57 2 (2002) 169-183
83. Kvols L.K., Moertel C.G., O'Connell M.J., et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315 11 (1986) 663-666
84. Oberg K., Funa K., and Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. New England Journal of Medicine 309 3 (1983) 129-133
85. Oberg K., and Eriksson B. The role of interferons in the management of carcinoid tumours. British Journal of Haematology 79 Suppl. 1 (1991) 74-77
86. Lips C.J., Lentjes E.G., and Hoppener J.W. The spectrum of carcinoid tumours and carcinoid syndromes. Annals of Clinical Biochemistry 40 Pt 6 (2003) 612-627
87. Breedis C., and Young G. The blood supply of neoplasms in the liver. American Journal of Pathology 30 5 (1954) 969-977
88. Ackerman N.B. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75 4 (1974) 589-596
89. Ramsey D.E., Kernagis L.Y., Soulen M.C., and Geschwind J.F. Chemoembolization of hepatocellular carcinoma. Journal of Vascular and Interventional Radiology 13 9 Pt 2 (2002) S211-S221
90. Pentecost M.J., Daniels J.R., Teitelbaum G.P., and Stanley P. Hepatic chemoembolization: safety with portal vein thrombosis. Journal of Vascular and Interventional Radiology 4 3 (1993) 347-351
91. Cormier J.N., Thomas K.T., Chari R.S., and Pinson C.W. Management of hepatocellular carcinoma. Journal of Gastrointestinal Surgery 10 5 (2006) 761-780
92. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 9319 (2002) 1734-1739
93. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 5 (2002) 1164-1171
94. Rougier P., Mitry E., Barbare J.C., and Taieb J. Hepatocellular carcinoma (HCC): an update. Seminars in Oncology 34 2 Suppl. 1 (2007) S12-S20
95. Smith G.W., Bukowski R.M., Hewlett J.S., and Groppe C.W. Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer 54 8 (1984) 1513-1516
96. Tanaka N., Yamakado K., Nakatsuka A., et al. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma-initial experience. European Journal of Radiology 41 1 (2002) 42-48
97. Cantore M., Mambrini A., Fiorentini G., et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 103 7 (2005) 1402-1407
98. Burger I., Hong K., Schulick R., et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. Journal of Vascular and Interventional Radiology 16 3 (2005) 353-361
99. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Journal of Clinical Oncology 23 22 (2005) 4888-4896
100. Ensminger W.D. A role for hepatic-directed chemotherapy in colorectal liver metastases. Journal of Clinical Oncology 23 22 (2005) 4815-4817
101. Muller H., Nakchbandi V., Chatzisavvidis I., and von Voigt C. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Hepatogastroenterology 50 54 (2003) 1919-1926
102. Salman H.S., Cynamon J., Jagust M., et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clinical Colorectal Cancer 2 3 (2002) 173-179
103. Gupta S., Yao J.C., Ahrar K., et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer Journal 9 4 (2003) 261-267
104. Ajani J.A., Carrasco C.H., Charnsangavej C., et al. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Annals of Internal Medicine 108 3 (1988) 340-344
105. Hajarizadeh H., Ivancev K., Mueller C.R., et al. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. American Journal of Surgery 163 5 (1992) 479-483
106. Ruszniewski P., Rougier P., Roche A., et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71 8 (1993) 2624-2630
107. Perry L.J., Stuart K., Stokes K.R., and Clouse M.E. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116 6 (1994) 1111-1116 discussion 1116-7
108. Clouse M.E., Perry L., Stuart K., and Stokes K.R. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55 Suppl. 3 (1994) 92-97
109. Ho A.S., Picus J., Darcy M.D., et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. American Journal of Roentgenology 188 5 (2007) 1201-1207
110. Seong J., Park H.C., Han K.H., et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatology Research 27 1 (2003) 30-35
111. Zeng Z.C., Tang Z.Y., Fan J., et al. Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. Japanese Journal of Clinical Oncology 35 2 (2005) 61-67
112. Roca E.L., Okazaki N., Okada S., et al. Radiotherapy for bone metastases of hepatocellular carcinoma. Japanese Journal of Clinical Oncology 22 2 (1992) 113-116
113. Kaizu T., Karasawa K., Tanaka Y., et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. American Journal of Gastroenterology 93 11 (1998) 2167-2171
114. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. International Journal of Radiation Oncology, Biology, and Physics 21 1 (1991) 109-122
115. Lawrence T.S., Robertson J.M., Anscher M.S., et al. Hepatic toxicity resulting from cancer treatment. International Journal of Radiation Oncology, Biology, and Physics 31 5 (1995) 1237-1248
116. Giraud P., Yorke E., Jiang S., et al. Reduction of organ motion effects in IMRT and conformal 3D radiation delivery by using gating and tracking techniques. Cancer Radiotherapy 10 5 (2006) 269-282
117. Lawrence T.S., Ten Haken R.K., Kessler M.L., et al. The use of 3-D dose volume analysis to predict radiation hepatitis. International Journal of Radiation Oncology, Biology, and Physics 23 4 (1992) 781-788
118. Lawrence T.S., Tesser R.J., and ten Haken R.K. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. International Journal of Radiation Oncology, Biology, and Physics 19 4 (1990) 1041-1047
119. Fuss M., Salter B.J., Cavanaugh S.X., et al. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. International Journal of Radiation Oncology, Biology, and Physics 59 4 (2004) 1245-1256
120. Hawkins M.A., and Dawson L.A. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106 8 (2006) 1653-1663
121. Szyszko T., Al-Nahhas A., Tait P., et al. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nuclear Medicine Communications 28 1 (2007) 21-24
122. Murthy R., Xiong H., Nunez R., et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. Journal of Vascular and Interventional Radiology 16 7 (2005) 937-945
123. Salem R., Thurston K.G., Carr B.I., et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. Journal of Vascular and Interventional Radiology 13 9 Pt 2 (2002) S223-S229
124. Pitt H.A., Nakeeb A., Abrams R.A., et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Annals of Surgery 221 6 (1995) 788-797 discussion 797-8
125. Ben-Josef E., Normolle D., Ensminger W.D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. Journal of Clinical Oncology 23 34 (2005) 8739-8747
126. Kuvshinoff B.W., Armstrong J.G., Fong Y., et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. British Journal of Surgery 82 11 (1995) 1522-1525
127. Vallis K.A., Benjamin I.S., Munro A.J., et al. External beam and intraluminal radiotherapy for locally advanced bile duct cancer: role and tolerability. Radiotherapy and Oncology 41 1 (1996) 61-66
128. Ishii H., Furuse J., Nagase M., et al. Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology 51 58 (2004) 954-957
129. Foo M.L., Gunderson L.L., Bender C.E., and Buskirk S.J. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. International Journal of Radiation Oncology, Biology, and Physics 39 4 (1997) 929-935
130. Krishnan S., Lin E.H., Gunn G.B., et al. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. American Journal of Clinical Oncology 29 6 (2006) 562-567
131. Blomgren H., Lax I., Naslund I., and Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncologica 34 6 (1995) 861-870
132. Wulf J., Hadinger U., Oppitz U., et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlentherapie und Onkologie 177 12 (2001) 645-655
133. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. Journal of Clinical Oncology 18 11 (2000) 2210-2218
134. Mohiuddin M., Chen E., and Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. Journal of Clinical Oncology 14 3 (1996) 722-728
135. Dawson L.A., Normolle D., Balter J.M., et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. International Journal of Radiation Oncology, Biology, and Physics 53 4 (2002) 810-821
136. Dawson L.A., McGinn C.J., and Lawrence T.S. Conformal chemoradiation for primary and metastatic liver malignancies. Seminars in Surgical Oncology 21 4 (2003) 249-255
137. Sharma R.A., Van Hazel G.A., Morgan B., et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. Journal of Clinical Oncology 25 9 (2007) 1099-1106
138. McStay M.K., Maudgil D., Williams M., et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 237 2 (2005) 718-726
139. Liapi E., and Geschwind J.F. Transcatheter and ablative therapeutic approaches for solid malignancies. Journal of Clinical Oncology 25 8 (2007) 978-986
140. Erce C., and Parks R.W. Interstitial ablative techniques for hepatic tumours. British Journal of Surgery 90 3 (2003) 272-289
141. Zoepf T., Jakobs R., Arnold J.C., et al. Photodynamic therapy for palliation of nonresectable bile duct cancer-preliminary results with a new diode laser system. American Journal of Gastroenterology 96 7 (2001) 2093-2097
142. Berr F., Wiedmann M., Tannapfel A., et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 31 2 (2000) 291-298
143. Yamasaki T., Kimura T., Kurokawa F., et al. Percutaneous radiofrequency ablation with cooled electrodes combined with hepatic arterial balloon occlusion in hepatocellular carcinoma. Journal of Gastroenterology 40 2 (2005) 171-178
144. Yamasaki T., Kurokawa F., Shirahashi H., et al. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer 95 11 (2002) 2353-2360
145. de Baere T., Bessoud B., Dromain C., et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. American Journal of Roentgenology 178 1 (2002) 53-59
146. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210 3 (1999) 655-661
147. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 1 (2005) 122-130
148. Pearson A.S., Izzo F., Fleming R.Y., et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. American Journal of Surgery 178 6 (1999) 592-599
149. Liang P., Dong B., Yu X., et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 235 1 (2005) 299-307
150. Zgodzinski W., and Espat N.J. Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma. World Journal of Gastroenterology 11 33 (2005) 5239-5240
151. Chiou Y.-Y., Hwang J.-I., Wang H.-K., et al. Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung Journal of Medical Sciences 21 (2005) 304-309
152. Slakey D.P. Radiofrequency ablation of recurrent cholangiocarcinoma. American Surgeon 68 4 (2002) 395-397
153. Khatri V.P., and McGahan J. Non-resection approaches for colorectal liver metastases. Surgical Clinics of North America 84 2 (2004) 587-606
154. Ortner M.E., Caca K., Berr F., et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125 5 (2003) 1355-1363
155. Zoepf T., Jakobs R., Arnold J.C., et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. American Journal of Gastroenterology 100 11 (2005) 2426-2430
156. Berber E., Flesher N., and Siperstein A.E. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World Journal of Surgery 26 8 (2002) 985-990
157. Gillams A., Cassoni A., Conway G., and Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdominal Imaging 30 4 (2005) 435-441
158. Gines P., Quintero E., Arroyo V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 7 1 (1987) 122-128
159. Rosenberg S.M. Palliation of malignant ascites. Gastroenterology Clinics of North America 35 1 (2006) 189-199 xi
160. Bergasa N.V. Medical palliation of the jaundiced patient with pruritus. Gastroenterology Clinics of North America 35 1 (2006) 113-123
161. Singh N., Gayowski T., Wagener M.M., and Marino I.R. Depression in patients with cirrhosis. Impact on outcome. Digestive Diseases and Sciences 42 7 (1997) 1421-1427
162. Fromigue J., De Baere T., Baudin E., et al. Chemoembolization for liver metastases from medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 7 (2006) 2496-2499
163. Strosberg J.R., Choi J., Cantor A.B., and Kvols L.K. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 13 1 (2006) 72-78
164. Gupta S., Johnson M.M., Murthy R., et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 8 (2005) 1590-1602
165. Roche A., Girish B.V., de Baere T., et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. European Radiology 13 1 (2003) 136-140
166. Loewe C., Schindl M., Cejna M., et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. American Journal of Roentgenology 180 5 (2003) 1379-1384